tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2023 May 3;10(6)
fad240.
doi: 10.1093/ofid/ofad240. eCollection 2023 Jun. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
Takeshi Arashiro[SUP] 1 2 3 4 [/SUP], Yuzo Arima[SUP] 1 [/SUP], Jin Kuramochi[SUP] 5 6 [/SUP], Hirokazu Muraoka[SUP] 7 [/SUP], Akihiro Sato[SUP] 8 [/SUP], Kumi Chubachi[SUP] 9 [/SUP], Atsushi Yanai[SUP] 10 [/SUP], Hiroko Arioka[SUP] 10 [/SUP], Yuki Uehara[SUP] 11 12 [/SUP], Genei Ihara[SUP] 13 [/SUP], Yasuyuki Kato[SUP] 14 [/SUP], Naoki Yanagisawa[SUP] 15 [/SUP], Akihiro Ueda[SUP] 16 [/SUP], Hideaki Kato[SUP] 17 [/SUP], Hideaki Oka[SUP] 18 [/SUP], Yusuke Nishida[SUP] 18 [/SUP], Yuki Nidaira[SUP] 5 [/SUP], Takahiro Asami[SUP] 19 [/SUP], Torahiko Jinta[SUP] 20 [/SUP], Akira Nakamura[SUP] 21 [/SUP], Kunihiro Oba[SUP] 22 [/SUP], Daisuke Taniyama[SUP] 23 [/SUP], Kei Yamamoto[SUP] 18 [/SUP], Katsushi Tanaka[SUP] 17 [/SUP], Kankuro Ueshima[SUP] 24 [/SUP], Tetsuji Fuwa[SUP] 24 [/SUP], Ashley Stucky[SUP] 1 [/SUP], Tadaki Suzuki[SUP] 2 [/SUP], Chris Smith[SUP] 3 4 [/SUP], Martin Hibberd[SUP] 3 [/SUP], Koya Ariyoshi[SUP] 4 [/SUP], Motoi Suzuki[SUP] 1 [/SUP]
Affiliations
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 variants; test-negative design; vaccine effectiveness.
. 2023 May 3;10(6)
fad240.doi: 10.1093/ofid/ofad240. eCollection 2023 Jun. Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
Takeshi Arashiro[SUP] 1 2 3 4 [/SUP], Yuzo Arima[SUP] 1 [/SUP], Jin Kuramochi[SUP] 5 6 [/SUP], Hirokazu Muraoka[SUP] 7 [/SUP], Akihiro Sato[SUP] 8 [/SUP], Kumi Chubachi[SUP] 9 [/SUP], Atsushi Yanai[SUP] 10 [/SUP], Hiroko Arioka[SUP] 10 [/SUP], Yuki Uehara[SUP] 11 12 [/SUP], Genei Ihara[SUP] 13 [/SUP], Yasuyuki Kato[SUP] 14 [/SUP], Naoki Yanagisawa[SUP] 15 [/SUP], Akihiro Ueda[SUP] 16 [/SUP], Hideaki Kato[SUP] 17 [/SUP], Hideaki Oka[SUP] 18 [/SUP], Yusuke Nishida[SUP] 18 [/SUP], Yuki Nidaira[SUP] 5 [/SUP], Takahiro Asami[SUP] 19 [/SUP], Torahiko Jinta[SUP] 20 [/SUP], Akira Nakamura[SUP] 21 [/SUP], Kunihiro Oba[SUP] 22 [/SUP], Daisuke Taniyama[SUP] 23 [/SUP], Kei Yamamoto[SUP] 18 [/SUP], Katsushi Tanaka[SUP] 17 [/SUP], Kankuro Ueshima[SUP] 24 [/SUP], Tetsuji Fuwa[SUP] 24 [/SUP], Ashley Stucky[SUP] 1 [/SUP], Tadaki Suzuki[SUP] 2 [/SUP], Chris Smith[SUP] 3 4 [/SUP], Martin Hibberd[SUP] 3 [/SUP], Koya Ariyoshi[SUP] 4 [/SUP], Motoi Suzuki[SUP] 1 [/SUP]
Affiliations
- PMID: 37351451
- PMCID: PMC10284337
- DOI: 10.1093/ofid/ofad240
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
Keywords: COVID-19; SARS-CoV-2; SARS-CoV-2 variants; test-negative design; vaccine effectiveness.